Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.

ABSTRACT: Glioblastomas (GBMs) are high-grade brain tumors, differentially driven by alterations (amplification, deletion or missense mutations) in the epidermal growth factor receptor (EGFR), that carry a poor prognosis of just 12-15 months following standard therapy. A combination of interventions targeting tumor-specific cell surface regulators along with convergent downstream signaling pathways may enhance treatment efficacy. Against this background, we investigated a novel photoimmunotherapy approach combining the cytotoxicity of photodynamic therapy with the specificity of immunotherapy. An EGFR-specific affibody (Z_EGFR:03115 ) was conjugated to the phthalocyanine dye, IR700DX, which when excited with near-infrared light produces a cytotoxic response. Z_EGFR:03115 -IR700DX

SUBMITTER: Burley TA 

PROVIDER: S-EPMC6016485 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature